X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (42) 42
humans (41) 41
female (32) 32
oncology (29) 29
middle aged (23) 23
aged (18) 18
cancer (17) 17
male (17) 17
treatment outcome (17) 17
chemistry (16) 16
metallurgy (16) 16
organic chemistry (16) 16
survival (15) 15
adult (14) 14
peptides (14) 14
carcinoma, renal cell - drug therapy (12) 12
carcinoma, renal cell - genetics (12) 12
kidney neoplasms - genetics (12) 12
antineoplastic agents - therapeutic use (11) 11
carcinoma (10) 10
kidney neoplasms - drug therapy (10) 10
mutation (10) 10
neoplasm metastasis (10) 10
sunitinib (10) 10
carcinoma, renal cell - pathology (9) 9
care and treatment (9) 9
disease-free survival (9) 9
aged, 80 and over (8) 8
chemotherapy (8) 8
indoles - therapeutic use (8) 8
kidney neoplasms - pathology (8) 8
metastasis (8) 8
prognosis (8) 8
pyrroles - therapeutic use (8) 8
analysis (7) 7
biomarkers (7) 7
hematology, oncology and palliative medicine (7) 7
ovarian cancer (7) 7
ovarian neoplasms - pathology (7) 7
polymorphism, single nucleotide (7) 7
antineoplastic agents - adverse effects (6) 6
breast-cancer (6) 6
cancer therapies (6) 6
expression (6) 6
hypertension (6) 6
ovarian neoplasms - genetics (6) 6
pharmacology & pharmacy (6) 6
prospective studies (6) 6
urology (6) 6
1st-line sunitinib (5) 5
carcinoma, ovarian epithelial (5) 5
clinical medicine (5) 5
interferon-alpha (5) 5
metastases (5) 5
paclitaxel (5) 5
patients (5) 5
pharmacokinetics (5) 5
proportional hazards models (5) 5
protein kinase inhibitors - therapeutic use (5) 5
research (5) 5
spain (5) 5
therapy (5) 5
tumors (5) 5
tyrosine kinase inhibitor (5) 5
urology & nephrology (5) 5
women (5) 5
antineoplastic agents (4) 4
antineoplastic combined chemotherapy protocols - therapeutic use (4) 4
bevacizumab (4) 4
biomarker (4) 4
brca1 (4) 4
carcinoma, renal cell (4) 4
cytochrome p-450 cyp3a - genetics (4) 4
docetaxel (4) 4
double-blind (4) 4
efficacy (4) 4
gene expression (4) 4
genetic aspects (4) 4
health aspects (4) 4
identification (4) 4
kidney cancer (4) 4
medical and health sciences (4) 4
medical prognosis (4) 4
medicin och hälsovetenskap (4) 4
metastatic renal cell carcinoma (4) 4
neoplasm grading (4) 4
obstetrics & gynecology (4) 4
pharmacogenetics (4) 4
protein-tyrosine kinase (4) 4
research article (4) 4
single nucleotide polymorphisms (4) 4
single-nucleotide polymorphisms (4) 4
studies (4) 4
survival rate (4) 4
toxicity (4) 4
abridged index medicus (3) 3
antimitotic agents (3) 3
antineoplastic combined chemotherapy protocols - adverse effects (3) 3
association (3) 3
beer (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 12, pp. 1143 - 1150
Summary Background Sunitinib is a tyrosine kinase inhibitor with proven efficacy in renal-cell carcinoma, but some patients do not respond or need dose... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | VARIABILITY | INTERFERON-ALPHA | EFFICACY | ANGIOGENESIS | BIOMARKER | ONCOLOGY | GENOTYPE | VEGF | EXPRESSION | EXPOSURE | Predictive Value of Tests | Kidney Neoplasms - genetics | Prospective Studies | Humans | Middle Aged | Carcinoma, Renal Cell - genetics | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Patient Selection | Sunitinib | Cytochrome P-450 CYP3A - genetics | Time Factors | Antineoplastic Agents - adverse effects | Pyrroles - adverse effects | Female | Antineoplastic Agents - pharmacokinetics | Carcinoma, Renal Cell - drug therapy | Pyrroles - therapeutic use | Precision Medicine | Protein Kinase Inhibitors - pharmacokinetics | Genetic Predisposition to Disease | Risk Assessment | Carcinoma, Renal Cell - pathology | Gene Frequency | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Logistic Models | Treatment Outcome | Spain | Disease-Free Survival | Homozygote | Phenotype | Indoles - adverse effects | Protein Kinase Inhibitors - therapeutic use | Heterozygote | Indoles - therapeutic use | Kidney Neoplasms - pathology | Aged | Polymorphism, Single Nucleotide | Kidney Neoplasms - drug therapy | Vascular Endothelial Growth Factor Receptor-3 - genetics | Genetic markers | Carcinoma | Toxicity | Oncology | Single-nucleotide polymorphism | Gene polymorphism | Protein-tyrosine kinase | Survival | Interleukin 8 | Vascular endothelial growth factor receptors | Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 5, pp. 672,681a - 681,681a
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2018, Volume 378, Issue 17, pp. 1653 - 1654
To the Editor: We agree with most of the content in the review article by Sartor and de Bono (Feb. 15 issue), 1 and we consider the conclusions provided by the... 
MEDICINE, GENERAL & INTERNAL | Cell Line, Tumor | Prostatic Neoplasms | Male | Neoplasm Metastasis | Humans
Journal Article
by Coleman, Robert L and Coleman, R L and Oza, Amit M and Oza, A M and Lorusso, D and Lorusso, Domenica and Aghajanian, C and Aghajanian, Carol and Oaknin, A and Oaknin, Ana and Dean, A and Dean, Andrew and Colombo, N and Colombo, Nicoletta and Weberpals, Johanne I and Weberpals, J I and Clamp, Andrew and Clamp, A and Scambia, Giovanni and Scambia, G and Leary, A and Leary, Alexandra and Holloway, Robert W and Holloway, R W and Gancedo, M Amenedo and Gancedo, Margarita Amenedo and Fong, Peter C and Fong, P C and Goh, Jeffrey C and Goh, J C and O'Malley, David M and O'Malley, D M and Armstrong, Deborah K and Armstrong, D K and Garcia-Donas, Jesus and Garcia-Donas, J and Swisher, E M and Swisher, Elizabeth M and Floquet, A and Floquet, Anne and Konecny, Gottfried E and Konecny, G E and McNeish, I A and McNeish, Iain A and Scott, C L and Scott, Clare L and Cameron, Terri and Maloney, Lara and Isaacson, Jeff and Goble, Sandra and Grace, Caroline and Harding, Thomas C and Raponi, Mitch and Sun, James and Lin, Kevin K and Giordano, Heidi and Ledermann, J A and Ledermann, Jonathan A and Buck, M and Friedlander, M L and Harnett, P and Kichenadasse, G and Denys, H and Dirix, L and Vergote, I and Elit, L and Ghatage, P and Plante, M and Provencher, D and Welch, S and Gladieff, L and Joly, F and Lortholary, A and Lotz, J and Medioni, J and Tredan, O and You, B and El-Balat, A and Hänle, C and Krabisch, P and Neunhöffer, T and Pölcher, M and Wimberger, P and Amit, A and Kovel, S and Leviov, M and Safra, T and Shapira-Frommer, R and Stemmer, S and Bologna, A and Pignata, S and Sabbatini, R F and Tamberi, S and Zamagni, C and O'Donnell, A and Herraez, A Casado and Guerra, E M and Palacio, I and Romero, I and Sanchez, A and ... and ARIEL3 Investigators and ARIEL3 investigators
The Lancet, ISSN 0140-6736, 10/2017, Volume 390, Issue 10106, pp. 1949 - 1961
Rucaparib, a poly(ADP-ribose) polymerase inhibitor, has anticancer activity in recurrent ovarian carcinoma harbouring a mutation or high percentage of... 
MEDICINE, GENERAL & INTERNAL | MULTICENTER | SOLID TUMORS | BEVACIZUMAB | OPEN-LABEL | CANCER | HETEROZYGOSITY | EPITHELIAL OVARIAN | CHEMOTHERAPY | Double-Blind Method | Follow-Up Studies | Risk Assessment | Humans | Middle Aged | Ovarian Neoplasms - pathology | Neoplasm Recurrence, Local - drug therapy | Survival Rate | Treatment Outcome | Ovarian Neoplasms - mortality | Neoplasm Recurrence, Local - mortality | Indoles - administration & dosage | Poly(ADP-ribose) Polymerase Inhibitors - administration & dosage | Neoplasm Recurrence, Local - pathology | Disease-Free Survival | Maintenance Chemotherapy - methods | Internationality | Ovarian Neoplasms - therapy | Female | Aged | Molecular Targeted Therapy - methods | Clinical trials | Care and treatment | Carcinoma | Drug therapy | Ovarian cancer | Cancer | Analysis | Chemotherapy | Ovarian carcinoma | Platinum | Biomarkers | Mutation | Cancer therapies | Tumors | Homologous recombination | Central nervous system | Poly(ADP-ribose) | Homology | Genomes | Fallopian tube | ADP | Anticancer properties | Metastases | Homologous recombination repair | Randomization | Pain | Motivation | Ribose | Hemoglobin | Alanine | Anemia | Poly(ADP-ribose) polymerase | Breast cancer | Patients | Survival | Heterozygosity | Abdomen | Polymerase | Inhibitors | Point mutation | Loss of heterozygosity | Antitumor activity | Aspartate aminotransferase | Peritoneum
Journal Article
Nature Communications, ISSN 2041-1723, 09/2015, Volume 6, Issue 1, p. 8383
Journal Article
European Journal of Clinical Pharmacology, ISSN 0031-6970, 12/2015, Volume 71, Issue 12, pp. 1477 - 1484
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 09/2017, Volume 23, Issue 17, pp. 5320 - 5320
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2019, Volume 381, Issue 4, pp. 338 - 348
Erdafitinib, an inhibitor of fibroblast growth factor receptor, was tested in previously treated patients with advanced urothelial cancer with FGFR... 
MEDICINE, GENERAL & INTERNAL | PHASE-II TRIAL | MULTICENTER | THERAPY | COMPREHENSIVE MOLECULAR CHARACTERIZATION | JNJ-42756493 | CHEMOTHERAPY | Cancer patients | Diagnosis | Bladder cancer | Health aspects
Journal Article
The New England journal of medicine, 04/2018, Volume 378, Issue 17, p. 1653
Journal Article
PLoS ONE, ISSN 1932-6203, 01/2014, Volume 9, Issue 1, p. e86263
Purpose: To identify tissue microRNAs predictive of sunitinib activity in patients with metastatic renal-cell-carcinoma (MRCC) and to evaluate in vitro their... 
SURVIVAL | INTERFERON | CANCER-PATIENTS | ASSOCIATIONS | 1ST-LINE SUNITINIB | MULTIDISCIPLINARY SCIENCES | MATRIX-METALLOPROTEINASE-9 | TARGETS | SELECTION | EXPRESSION | PROGRESSION | Kidney Neoplasms - genetics | Prognosis | Humans | Middle Aged | Carcinoma, Renal Cell - genetics | Male | Antineoplastic Agents - therapeutic use | Gene Expression Profiling | Vascular Endothelial Growth Factor A - secretion | Neoplasm Metastasis | Aged, 80 and over | Adult | Female | Indoles - pharmacology | Matrix Metalloproteinase 9 - secretion | Antineoplastic Agents - pharmacology | Carcinoma, Renal Cell - drug therapy | Pyrroles - therapeutic use | Reproducibility of Results | Paracrine Communication | Carcinoma, Renal Cell - pathology | Treatment Outcome | Kidney Neoplasms - mortality | Carcinoma, Renal Cell - mortality | Drug Resistance, Neoplasm - genetics | Pyrroles - pharmacology | Models, Biological | Cell Line, Tumor | Indoles - therapeutic use | Kidney Neoplasms - pathology | Aged | MicroRNAs - genetics | Kidney Neoplasms - drug therapy | Antimitotic agents | Care and treatment | MicroRNA | Carcinoma | Analysis | Metastasis | Antineoplastic agents | Vascular endothelial growth factor | Cancer | Cell survival | Effectiveness | Secretion | MiRNA | Paracrine signalling | Oncology | Gene expression | Cancer therapies | Patients | Gelatinase B | Metastases | MicroRNAs | Medical prognosis | Predictions | Biomarkers | Prostate cancer | Bioinformatics | Cell migration | Clear cell-type renal cell carcinoma | Tumors | Kidney transplantation | Phenotype | RNA | Fenotip | Renal cancer | Càncer de ronyó | Resistència als medicaments | Marcadors bioquímics | Micro RNAs | Drug resistance | Biochemical markers
Journal Article